Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Vitamin A Palmitate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : National Institutes of Health
Deal Size : $3.0 million
Deal Type : Funding
Advent Therapeutics Awarded $3 Million NIH Grant for Novel Neonatal Lung Therapy
Details : The grant will allow the Company to position its novel aerosolized retinol palmitate (vitamin A) formulation for commercialization in 2025 to prevent Bronchopulmonary Dysplasia (BPD).
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 18, 2023
Lead Product(s) : Vitamin A Palmitate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : National Institutes of Health
Deal Size : $3.0 million
Deal Type : Funding
Lead Product(s) : ChAdOx1
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : The Jenner Institute, Oxford University
Deal Size : Undisclosed
Deal Type : Agreement
The Jenner Institute signs an agreement with Advent to develop a novel coronavirus vaccine
Details : The Jenner Institute at the University of Oxford has agreed a contract with Advent Srl, to produce the first batch of the novel coronavirus vaccine ChAdOx1 nCoV-19 for clinical testing.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
February 11, 2020
Lead Product(s) : ChAdOx1
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : The Jenner Institute, Oxford University
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?